Reports Q3 revenue $35,000, consensus $11,670. AIM CEO Thomas Equels stated, “We are driving significant momentum across multiple clinical programs and studies that are demonstrating Ampligen’s significant potential to address high value and high need indications, especially in the pancreatic cancer space. Over the course of 2024, our team has made important progress in executing our clinical strategy, facilitating potential partnerships with big pharma and leveraging commercialization opportunities to create value. Our Board of Directors is dedicated to helping patients in need and delivering enhanced value for our shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech stockholder Kellner Group issues letter on Board vote
- Aim Immunotech Inc. (AIM) Q3 Earnings Cheat Sheet
- AIM ImmunoTech price target lowered to $1 from $2 at Maxim
- AIM ImmunoTech granted U.S. patent for Ampligen for endometriosis treatment
- AIM ImmunoTech prices 4.65M shares at 27c in registered direct offering